Dr. Reddy's Laboratories Limited (RDY) Stock Analysis & Investment Frameworks
Dr. Reddy's Laboratories Limited (RDY) stock analysis on Invetso. Review Dr. Reddy's Laboratories Limited’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Dr. Reddy's Laboratories Limited Company Overview
- Exchange: New York Stock Exchange
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: IN
Dr. Reddy's Laboratories Limited Key Financial Metrics
- Market Cap: $12.10B
- Revenue: $3.76B
- P/E Ratio: 25.05
- ROE: 7.37%
- ROIC: 4.83%
- Dividend Yield: 0.58%
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
Dr. Reddy's Laboratories Limited Investment Frameworks
Invetso analyzes Dr. Reddy's Laboratories Limited (RDY) across the following frameworks:
- Dr. Reddy's Laboratories Limited 10Y Growth Potential
- Dr. Reddy's Laboratories Limited Scenario Analysis
- Dr. Reddy's Laboratories Limited Risks & Opportunities
- Dr. Reddy's Laboratories Limited Economic Moat
- Dr. Reddy's Laboratories Limited Business Model
- Dr. Reddy's Laboratories Limited Management
- Dr. Reddy's Laboratories Limited SWOT Analysis
- Dr. Reddy's Laboratories Limited Porter's 5 Forces
- Dr. Reddy's Laboratories Limited PESTLE Analysis
- Dr. Reddy's Laboratories Limited ESG Analysis